Gender and Drug-Resistant Tuberculosis in Nigeria


Journal article


O. Oladimeji, B. Atiba, F. Anyiam, Babatunde A. Odugbemi, T. Afolaranmi, A. Zoakah, C. Horsburgh
Tropical Medicine and Infectious Disease, 2023

Semantic Scholar DOI PubMedCentral PubMed
Cite

Cite

APA   Click to copy
Oladimeji, O., Atiba, B., Anyiam, F., Odugbemi, B. A., Afolaranmi, T., Zoakah, A., & Horsburgh, C. (2023). Gender and Drug-Resistant Tuberculosis in Nigeria. Tropical Medicine and Infectious Disease.


Chicago/Turabian   Click to copy
Oladimeji, O., B. Atiba, F. Anyiam, Babatunde A. Odugbemi, T. Afolaranmi, A. Zoakah, and C. Horsburgh. “Gender and Drug-Resistant Tuberculosis in Nigeria.” Tropical Medicine and Infectious Disease (2023).


MLA   Click to copy
Oladimeji, O., et al. “Gender and Drug-Resistant Tuberculosis in Nigeria.” Tropical Medicine and Infectious Disease, 2023.


BibTeX   Click to copy

@article{o2023a,
  title = {Gender and Drug-Resistant Tuberculosis in Nigeria},
  year = {2023},
  journal = {Tropical Medicine and Infectious Disease},
  author = {Oladimeji, O. and Atiba, B. and Anyiam, F. and Odugbemi, Babatunde A. and Afolaranmi, T. and Zoakah, A. and Horsburgh, C.}
}

Abstract

We conducted a retrospective study of 2555 DR-TB patients admitted to treatment between 2010 and 2016 in six geopolitical zones in Nigeria. We characterized the gender distribution of DR-TB cases and the association between demographics and clinical data, such as age, treatment category, number of previous TB treatment cycles, and geopolitical zone, with gender. The independent effects of being a male or female DR-TB patient were determined using bivariate and multivariate analyzes with statistical significance of p < 0.05 and a 95% confidence interval. Records from a total of 2555 DR-TB patients were examined for the study. A majority were male (66.9%), largest age-group was 30–39 years old (35.8%), most had MDR-TB (61.4%), were HIV-negative (76.6%), and previously treated for TB (77.1%). The southwest treatment zone had the highest proportion of DR-TB patients (36.9%), and most DR-TB diagnoses occurred in 2016 (36.9%). On bivariate analysis, age, HIV status, treatment zone, and clinical patient group in DR-TB were significantly associated with male gender. On multivariate analysis, males aged 20–29 years (AOR: 0.19, 95% CI: 0.33–0.59, p = 0.001) and HIV-positive males (AOR: 0.44, 95% CI: 0.33–0.59, p = 0.001) had lower likelihood of MDR-TB as males in the south–south treatment zone (AOR: 1.88, 95% CI: 1.23–2.85, p = 0.03), and being male and aged ≥60 years (AOR: 2.19, 95% CI: 1.05–4.54, p = 0.036) increased the probability of DR-TB. The older male population from south–southern Nigeria and women of childbearing age had lower incidence of DR-TB than men of the same age. Tailored interventions to reduce HIV and DR-TB prevalence in the general population, particularly among women of childbearing potential, and treatment support for young and older men are relevant strategies to reduce DR-TB in Nigeria.